Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research
- PMID: 19619345
- DOI: 10.1017/S026646230999002X
Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research
Abstract
Background: The concept of using public funds to pay for healthcare interventions only when provided in the context of ongoing research is receiving increasing attention worldwide. Nevertheless, these decisions are often controversial and implementation can be problematic.
Objectives: The aim of this study was to investigate the views of United Kingdom stakeholders on the current arrangements for implementing "only in research" (OIR) decisions and to investigate how improvements might be made.
Methods: After an internal review of previous OIR decisions issued by the National Institute for Health and Clinical Excellence (NICE), deliberations by NICE's Citizens Council, and an international workshop convened by NICE and the United States Agency for Healthcare Research and Quality, thirteen key stakeholders and experts from academia, industry, government, and the National Health Service (NHS) were interviewed using a semistructured interview guide. Interview transcripts were subjected to a framework-based analysis using computer-assisted qualitative data analysis software.
Results: All interviewees endorsed the use of the OIR option. There was a high degree of consensus for several suggestions regarding how the use of the OIR option might be improved. For example, there was universal agreement that a formal process should be established to prioritize research needs arising from OIR decisions and that funds for publicly funded research projects should be channeled in a manner that would better motivate healthcare providers to participate in OIR-related research.
Conclusions: The findings of this study suggest several potential modifications of the OIR pathway in the United Kingdom and may also be helpful to health technology assessment agencies in other countries that already use or are considering using an OIR-like option to reduce the uncertainty inherent in health technology assessment.
Similar articles
-
Informing a decision framework for when NICE should recommend the use of health technologies only in the context of an appropriately designed programme of evidence development.Health Technol Assess. 2012;16(46):1-323. doi: 10.3310/hta16460. Health Technol Assess. 2012. PMID: 23177626
-
Effects of the National Institute for Health and Clinical Excellence's technology appraisals on prescribing and net ingredient costs of drugs in the National Health Service in England.Int J Technol Assess Health Care. 2009 Jul;25(3):262-71. doi: 10.1017/S0266462309990110. Int J Technol Assess Health Care. 2009. PMID: 19619344
-
A research roadmap for complementary and alternative medicine - what we need to know by 2020.Forsch Komplementmed. 2014;21(2):e1-16. doi: 10.1159/000360744. Epub 2014 Mar 24. Forsch Komplementmed. 2014. PMID: 24851850
-
Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.Health Technol Assess. 2009 Jun;13(29):iii, ix-xi, 1-61. doi: 10.3310/hta13290. Health Technol Assess. 2009. PMID: 19500484 Review.
-
Public and patient involvement at the UK National Institute for Health and Clinical Excellence.Patient. 2011;4(1):1-10. doi: 10.2165/11586090-000000000-00000. Patient. 2011. PMID: 21766889 Review.
Cited by
-
Medical device assessment: scientific evidence examined by the French national agency for health - a descriptive study.BMC Public Health. 2012 Aug 1;12:585. doi: 10.1186/1471-2458-12-585. BMC Public Health. 2012. PMID: 22853740 Free PMC article. Review.
-
When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidance.Pharmacoeconomics. 2013 Feb;31(2):137-49. doi: 10.1007/s40273-012-0013-6. Pharmacoeconomics. 2013. PMID: 23329429 Free PMC article.
-
Evidence Following Conditional NICE Technology Appraisal Recommendations: A Critical Analysis of Methods, Quality and Risk of Bias.Pharmacoeconomics. 2024 Dec;42(12):1373-1394. doi: 10.1007/s40273-024-01418-3. Epub 2024 Sep 9. Pharmacoeconomics. 2024. PMID: 39249730 Free PMC article.
-
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers.Cancers (Basel). 2021 Feb 25;13(5):966. doi: 10.3390/cancers13050966. Cancers (Basel). 2021. PMID: 33669053 Free PMC article. Review.
-
Assessment of Pharmacogenomic Panel Assay for Prediction of Taxane Toxicities: Preliminary Results.Front Pharmacol. 2017 Nov 7;8:797. doi: 10.3389/fphar.2017.00797. eCollection 2017. Front Pharmacol. 2017. PMID: 29163177 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources